Lymphoma stem cells: A step toward a new therapeutic target by Kim, Seok Jin
211
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://dx.doi.org/10.5045/kjh.2011.46.4.211
The Korean Journal of Hematology
Volume 46ㆍNumber 4ㆍDecember 2011
Perspective
Lymphoma stem cells: A step 
toward a new therapeutic target
Seok Jin Kim, M.D., Ph.D.
Division of Hematology-Oncology, Department of Medicine, 
Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea
INTRODUCTION
Since lymphoma is a chemosensitive neoplasm, a complete 
response can be achieved by systemic chemotherapy, even 
in the metastatic setting. Even so, relapse occurs in a sub-
stantial number of patients with an apparently complete 
clinical response. It is therefore possible that a subset of 
lymphoma cells that remain viable during treatment causes 
the relapse. The cancer stem cell hypothesis postulates the 
presence of this specific cell population in cancers. It suggests 
that cancers are derived from cancer stem cells, which are 
a particular subset of cancer cells with stem-like properties, 
including self-renewal [1]. Since the existence of cancer 
stem cells was demonstrated in acute myeloid leukemia 
[2], various surface markers have been identified to isolate 
cancer stem cells from such solid cancers as breast, brain, 
and colon. Although a recent publication suggested the prob-
ability of lymphoma stem cells in non-Hodgkin lymphoma 
[3], it did not offer sufficient data to support the presence 
of cancer stem cells as an origin of lymphoma. However, 
given the potential role of cancer stem cells in the patho-
genesis of cancers, the possibility of lymphoma stem cells 
deserves attention, for it could improve our understanding 
of lymphoma biology and lead to the development of a 
new therapeutic target for lymphomas.
STEM CELLS IN HODGKIN LYMPHOMA
A small population of malignant cells, less than 1% of 
the total cells in this disease entity, is the hallmark of 
Hodgkin lymphoma. These malignant cells bear little pheno-
typic resemblance to normal B cells, including dim and 
variable CD20 expression. This unique nature of Hodgkin 
lymphoma has suggested the existence of lymphoma stem 
cells. A previous study has demonstrated the presence of 
a small population of CD20-positive B cells in 2 Hodgkin 
lymphoma cell lines, L428 and KM-H2 [4]. These cells 
showed high expression of aldehyde dehydrogenase 
(ALDH), a marker for cells having stem-like properties as 
well as the memory B-cell antigen CD27. The growth of 
Reed-Sternberg cells from an in vitro culture of these B 
cells provides evidence for their stem cell-like property. 
These clonal B cells with CD27
＋, and elevated ALDH were 
also detected in the peripheral blood of patients with classic 
Hodgkin lymphoma, although their clinical significance in 
Hodgkin lymphoma was not determined in this study. These 
results therefore strengthen evidence for the existence of 
lymphoma stem cells in Hodgkin lymphoma.
STEM CELLS IN NON-HODGKIN LYMPHOMA
Non-Hodgkin lymphoma refers to a group of heteroge-
neous disorders, including B cell and T/NK cell lymphomas. 
It is classified into various subtypes depending on the mor-
phologic, immunophenotypic, and clinical characteristics. 
These subtypes of non-Hodgkin lymphoma are associated 
with the specific developmental stages of the counterpart 
normal immune cells. For instance, errors in any of the 
immunoglobulin gene rearrangements during the devel-
opmental process of normal B cells may result in aberrant 
chromosomal translocations involving immunoglobulin 
heavy chain genes, which are characteristic of different Korean J Hematol 2011;46:211-3.
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Fig. 1. Primary cells from malignant ascites of a refractory B-cell non-Hodgkin lymphoma patient are sorted as a side population (P3) and a non-side
population (P4) using flow cytometry (A). The side population (P3) in the tail region of the dot plot is reduced when the cells are incubated with 
verapamil (B).
subtypes of B-cell non-Hodgkin lymphoma [5]. This implies 
that a subset of cells with a genetic mistake occurring during 
their development might be an origin of lymphoma, and 
suggests that they could play a role as lymphoma stem 
cells. However, the concept of cancer stem cells would 
not necessarily imply that the transformation of normal 
stem cells constitutes the initiating step of carcinogenesis. 
I f  n o r m a l  m a t u r e  c e l l s  c o u l d  a c q u i r e  s o m e  p r o p e r t i e s  o f  
normal stem cells after their transformation into premalig-
nant cells, they would re-express properties of stem cells, 
and then initiate cancers. Likewise, premalignant lymphoma 
cells might need additional genetic changes associated with 
stemness to become lymphoma stem cells. For example, 
the first chromosomal translocations could occur in mature 
lymphocytes within the germinal center, and these would 
need to accumulate secondary reprogramming mutations 
in order to develop germinal center-derived lymphomas.
SIDE POPULATION CELLS IN HODGKIN AND NON- 
HODGKIN LYMPHOMAS
Side population (SP) analysis has been used to exploit 
the presence of cancer stem cells for cancers that have 
no surface marker for stem cell isolation. This analysis is 
based on the peculiar characteristic of normal stem cells 
that allows them to protect themselves from cytotoxic agents 
via high expression of ATP-binding cassette (ABC) 
transporters. Thus, the SP is a sub-population of cells that 
extrude the cell-permeable DNA-specific dye, Hoechst 
33342, through an ABC transporter. The SP was recognized 
as a stem cell population, distinguishable from other such 
populations [6]. Such a distinguishing property supports 
that notion that cancer stem cells are associated with a 
resistance to chemotherapy and posttreatment relapse. 
Previous studies in several human and murine cancer cell 
lines have demonstrated that SP cells could be characterized 
as cancer stem cells. In Hodgkin lymphoma, the possibility 
of lymphoma stem cell population and the association of 
this population with resistance to chemotherapy have been 
reported. Thus, Hodgkin lymphoma cell lines contain SP 
cells, which are enriched for distinct small mononuclear 
cells and generate larger cells with Reed-Sternberg cell-like 
morphology [7]. In addition, the SP cells in Hodgkin lym-
phoma cell lines show increased resistance to gemcitabine, 
a drug commonly used to treat refractory Hodgkin lympho-
ma [8]. A study with a murine mantle cell lymphoma model 
also proposed that SP cells contain tumor-initiating cells 
responsible for lymphoma maintenance and dissemination 
[9]. Our own group has isolated SP cells from human B-cell 
non-Hodgkin lymphoma cell lines and from primary cells 
derived from refractory B-cell non-Hodgkin lymphoma pa-
tients (Fig. 1). In our study, the characteristics and gene 
expression profiles of SP cells were different from those 
of the main population within the same cell lines. All these 
results using SP analysis suggest the probability of a specific 
subset of lymphoma cells in Hodgkin and non-Hodgkin 
lymphoma that might be enriched with lymphoma stem 
cells.
CONCLUSIONS
The concept of cancer stem cells is changing our under-
standing of cancer biology. Thus, the identification of cancer 
stem cells may have profound effects on cancer diagnostics 
and therapeutics, changing the paradigm of management. 
The existence of lymphoma stem cells remains uncertain. 
However, if specific markers-such as the CD45＋CD19− 
cells proposed in a recent study as stem-like cells in human 
mantle cell lymphoma [10]-are identified, evidence in sup-
p o r t  o f  t h e  e x i s t e n c e  o f  l y m p h o m a  s t e m  c e l l s  m i g h t  b e  Korean J Hematol 2011;46:211-3.
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accumulated in the future. Thus, further studies to character-
ize lymphoma stem cells in lymphoma could contribute 
to the development of a new therapeutic target for 
lymphoma.
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